To date, immune checkpoint inhibitors targeting PD1/PDL1 and CTLA4 have transformed the care of patients with advanced-stage cancers, most effectively for melanoma, renal, head and neck, bladder, and Hodgkin lymphoma [9,27,28]. The gene discussed is PDCD1; the disease is cancer.